June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Therapeutic Efficacy of Topical Adiponectin-Derived Short Peptides and Globular Adiponectin for Experimental Dry Eye
Author Affiliations & Notes
  • Ying Li
    Department of ophthalmology, Chonnam National University Medical School & Hosp., Gwangju, Korea (the Republic of)
  • Lian Cui
    Department of ophthalmology, Chonnam National University Medical School & Hosp., Gwangju, Korea (the Republic of)
  • Hyo Seok Lee
    Department of ophthalmology, Chonnam National University Medical School & Hosp., Gwangju, Korea (the Republic of)
  • Henry H Hsu
    Allysta Pharmaceuticals, Belmont, California, United States
  • Laszlo Otvos
    Olpe LLC, Audubon, Pennsylvania, United States
  • Eva Surmacz
    Temple University, Philadelphia, Pennsylvania, United States
  • Kyung Chul Yoon
    Department of ophthalmology, Chonnam National University Medical School & Hosp., Gwangju, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Ying Li, None; Lian Cui, None; Hyo Seok Lee, None; Henry Hsu, None; Laszlo Otvos, None; Eva Surmacz, None; Kyung Chul Yoon, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 474. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Ying Li, Lian Cui, Hyo Seok Lee, Henry H Hsu, Laszlo Otvos, Eva Surmacz, Kyung Chul Yoon; Therapeutic Efficacy of Topical Adiponectin-Derived Short Peptides and Globular Adiponectin for Experimental Dry Eye. Invest. Ophthalmol. Vis. Sci. 2017;58(8):474.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the therapeutic effect of topical adiponectin (ADP)-derived short peptides and globular adiponectin in a mouse model of experimental dry eye (EDE).

Methods : EDE was created by desiccating stress in 6- to 8-weeks old female C57BL/6 mice. Eye drops containing 0.01% globular ADP, 0.01% ADP peptide 399 or 355, or balanced salt solution (BSS) were applied. Tear volume, tear film break-up time (TBUT), and corneal staining scores were measured at 5 and 10 days after treatment. Levels of IL-1β, IL-6, IFN-γ, CXCL-9, and CXCL-10 were measured in the conjunctiva using a multiplex immunobead assay at 10 days. Flow cytometric analysis for CD4+CCR5+ T cells was also performed.

Results : The globular ADP and both ADP-derived short peptide groups showed a significant improvement in tear volume, TBUT, corneal staining scores, and CD4+CCR5+ T cell infiltration compared with the EDE control and BSS-treated groups. Significantly decreased levels of IL-1β, CXCL-9, and CXCL-10 were observed in the globular ADP group compared with the EDE control. The 0.01% ADP peptide 399 and 355 treatment groups showed significantly decreased levels of IFN-γ, IL-1β, IL-6, CXCL-9, and CXCL-10 compared with the EDE control group and IFN-γ, IL-6, and CXCL-9 compared with the BSS group. However, there were no significant differences in all clinical and experimental parameters among the globular ADP and both ADP-derived short peptide groups.

Conclusions : Topical application of ADP-derived peptides could improve clinical signs and decrease inflammation of the ocular surface of EDE, and the effects were similar to those of globular ADP.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×